All In Biotech

NDA 205645 · Fresenius Kabi USA

Tigecycline

Tigecycline · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 1, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

23 Phase 3, 6 recruiting

FAERS reports

4,358

4,073 serious, 1,192 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • TIGECYCLINE · TIGECYCLINE 50MG/VIAL · POWDER, INTRAVENOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Tigecycline" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective638
  • off label use549
  • nausea302
  • drug resistance213
  • sepsis207
  • vomiting205
  • septic shock193
  • thrombocytopenia193
  • pathogen resistance172
  • product use in unapproved indication168
  • diarrhoea156
  • acute kidney injury153

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20068
200731
200863
200950
201037
201161
201271
201380
201479
2015151
2016107
2017216
2018241
2019404
2020360
2021419
2022332
2023417
2024518
2025413
2026298

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tigecycline (Tigecycline)

2024 spending

$2.4M

Beneficiaries

652

3,241 claims

Per beneficiary

$3,715

$19.85 per unit

View as table
YearSpending
2020$3,402,277
2021$3,640,666
2022$2,858,482
2023$3,491,734
2024$2,422,416

Part B: Tigecycline* (Tigecycline*) · HCPCS J3243

2024 spending

$40K

Beneficiaries

41

614 claims

Per beneficiary

$967

2024 ASP limit $0.63 per unit

View as table
YearSpending
2020$510,008
2021$318,211
2022$80,981
2023$48,843
2024$39,666

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 191 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.